CG
TRIB

Cutler Group’s Trinity Biotech TRIB Stock Holding History

Cutler Group’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,200
Closed -$14K – 7379
2016
Q2 		$14K Buy
+1,200
New +$67.6K ﹤0.01% 3777
2016
Q1 		– Sell
-320
Closed -$1K – 7209
2015
Q4 		$1K Buy
+320
New +$18.9K ﹤0.01% 6087

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Cutler Group's TRIB Position: Q4 2016 in Review

Cutler Group sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 100 shares — an estimated $3.44K sold.

Cutler Group first reported a position in TRIB in Q4 2015 and held it in 4 quarters. The position peaked at $7K in Q2 2016. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Cutler Group reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Cutler Group sold 100 Trinity Biotech shares in Q4 2016, an estimated $3.44K.
  • Cutler Group first reported a position in Trinity Biotech in Q4 2015 and held it in 4 quarters.
  • Cutler Group's Trinity Biotech position peaked at $7K in Q2 2016.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Cutler Group's 13F filing for Q4 2016, filed 12 Jan 2017.